Secondary Prevention of Cardiovascular Disease in the Elderly - SECURE

CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III0 个研究点目标入组 3,206 人开始时间: 2021年6月17日最近更新: 2021年8月2日

适应症

试验速览

暂无简介。

•1. Patients diagnosed with a type 1 myocardial infarction within the previous 8 weeks.
•2. Subjects must be =65 years old, presenting with at least one of the following additional conditions:
•I. Documented diabetes mellitus or previous treatment with oral hypoglycemic drugs or insulin.
•ii. Mild to moderate renal dysfunction: creatinine clearance 60-30 mL/min/1.73 m2.
•iii. Prior myocardial infarction: defined as an AMI occurring before the index event documented in a medical report.
•iv. Prior coronary revascularization: coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).
•v. Prior stroke: history of a documented stroke, defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue, not resulting in death.
•vi. Age = 75 years.
•3. Signing informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 3206

•1. Unable to sign informed consent.
•2. Contraindications to any of the components of the polypill.
•3. Living in a nursing home or committed to an institution by virtue of and order issued by the judicial or the administrative authorities.
•4. Mental illness limiting the capacity of self-care.
•5. Participating in another clinical trial.
•6. Severe congestive heart failure (NYHA III-IV).
•7. Severe renal disease (Creatinine Clearance (CrCl) <30ml/min/1.73 m2).
•8. Severe hepatic impairment. Liver cirrhosis transaminases exceeding 3 times the upper limit of the normal limit.
•9. Allergies to lactose, peanut, or soy.
•10. Need for oral anticoagulation at the time of randomization or planned in the future months.
•11. Any condition limiting life expectancy <2 years, including but not limited to active malignancy.
•12. Significant arrhythmias (including unresolved ventricular arrhythmias or atrial fibrillation).
•13. Scheduled coronary revascularization (patients can be randomized after final revascularization is completed within the pre-specified timeframe).
•14. Do not agree to the filing, forwarding and use of his/ her pseudonymised data.
•15. Individuals dependent from the sponsor, investigator or investigational site / institution.

发起方

CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III